1-乙基-5-苯基-4-咪唑啉 | 136802-73-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 1-乙基-5-苯基-4-咪唑啉
• 英文名称: 1-ethyl-5-phenyl-4-imidazoline
• 英文别名: 1-ethyl-5-phenyl-1H-imidazole-2-thiol；3-ethyl-4-phenyl-1H-imidazole-2-thione
• CAS: 136802-73-8
• 化学式: C₁₁H₁₂N₂S
• mdl: MFCD06655471
• 分子量: 204.296
• InChiKey: PQMVYAZFMXJQOM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.181
• 拓扑面积：
  47.4
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-乙基-5-苯基-4-咪唑啉 在 氢氧化钾 作用下， 以 乙醇 、 水 为溶剂， 反应 17.0h， 生成 2,5-二苯基吡嗪
  参考文献：
  名称：

  Korohoda, Maria Jolanta; Bojarska, Aleksandra Barbara, Journal fur praktische Chemie (Leipzig 1954), 1991, vol. 333, # 2, p. 355 - 360

  摘要：

  DOI：
• 作为产物：
  描述：

  异硫氰酸乙酯 、 α-Aminoacetophenone hydrobromide 在 三乙胺 作用下， 以 乙醇 为溶剂， 以81%的产率得到1-乙基-5-苯基-4-咪唑啉
  参考文献：
  名称：

  Korohoda, Maria Jolanta; Bojarska, Aleksandra Barbara, Journal fur praktische Chemie (Leipzig 1954), 1991, vol. 333, # 2, p. 355 - 360

  摘要：

  DOI：

文献信息

• Small molecules for the modulation of MCL-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US10000511B2

  公开（公告）日：2018-06-19

  This invention relates to compounds which selectively bind to the survival protein MCL-1 with high affinity and selectivity, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for modulating MCL-1 activity and for treating hyperproliferative disorders, angiogenesis disorders, cell cycle regulation disorders, autophagy regulation disorders, inflammatory disorders, and/or infectious disorders and/or for enhancing cellular engraftment and/or wound repair, as a sole agent or in combination with other active ingredients.

  本发明涉及以高亲和力和选择性与存活蛋白 MCL-1 选择性结合的化合物、含有此类化合物的药物组合物，以及使用这些化合物或组合物调节 MCL-1 活性和治疗过度增殖性疾病、血管生成疾病、细胞周期调节疾病、自噬调节疾病、炎症性疾病和/或感染性疾病和/或增强细胞移植和/或伤口修复，可作为单独制剂或与其他活性成分组合使用。
• Chemical entities that kill senescent cells for use in treating age-related disease
  申请人：Unity Biotechnology, Inc.

  公开号：US10195213B2

  公开（公告）日：2019-02-05

  Disclosed herein are compounds that are effective for treatment of various disease states associated with senescence. The disclosed compounds can be used to eliminate senescent cells for disease treatment. The dosing of the compounds includes both single administration and regimens of cycling dosages.

  本文公开的化合物可有效治疗与衰老有关的各种疾病状态。所公开的化合物可用于消除衰老细胞以治疗疾病。化合物的给药方式包括单次给药和循环给药。
• SMALL MOLECULES FOR THE MODULATION OF MCL-1 AND METHODS OF MODULATING CELL DEATH, CELL DIVISION, CELL DIFFERENTIATION AND METHODS OF TREATING DISORDERS
  申请人：Walensky Loren D.

  公开号：US20130035304A1

  公开（公告）日：2013-02-07

  This invention relates to compounds which selectively bind to the survival protein MCL-1 with high affinity and selectivity, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for modulating MCL-1 activity and for treating hyperproliferative disorders, angiogenesis disorders, cell cycle regulation disorders, autophagy regulation disorders, inflammatory disorders, and/or infectious disorders and/or for enhancing cellular engraftment and/or wound repair, as a sole agent or in combination with other active ingredients.
• METHODS AND COMPOSITIONS TO MODIFY GSK-3 ACTIVITY
  申请人：Ohio University

  公开号：US20170202818A1

  公开（公告）日：2017-07-20

  Methods for modulating GSK-3 activity and methods for treating a GSK-3-mediated disorder in a subject in need thereof. The methods include contacting a cell expressing GSK-3 with or administering to the subject in need a therapeutically effective amount of one or more compounds of General Formula (I) or General Formula (II): or pharmaceutically-acceptable salts or solvates thereof.
• COMPOUNDS AND THERAPEUTIC USES
  申请人：Unity Biotechnology, Inc.

  公开号：US20170281649A1

  公开（公告）日：2017-10-05

  Disclosed herein are compounds that are effective for treatment of various disease states associated with senescence. The disclosed compounds can be used to eliminate senescent cells for disease treatment. The dosing of the compounds includes both single administration and regimens of cycling dosages.